Aliases & Classifications for Sensory Peripheral Neuropathy

MalaCards integrated aliases for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 15
Sensory Neuropathy 12 74 29 54 6 15 71
Hereditary Sensory and Autonomic Neuropathies 71
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 34 356.2
MeSH 43 D009477
NCIt 49 C3501
SNOMED-CT 67 11442006 95662005
UMLS 71 C0027889 C0151313 C0699739

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to hereditary motor and sensory neuropathy, type iic and neuropathy, hereditary motor and sensory, russe type, and has symptoms including hyperesthesia, dysesthesia and sciatica. An important gene associated with Sensory Peripheral Neuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Methylcobalamin and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and skin, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Peripheral neuropathy, often shortened to neuropathy, is a general term describing disease affecting the... more...

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 639, show less)
# Related Disease Score Top Affiliating Genes
1 hereditary motor and sensory neuropathy, type iic 34.8 MPZ MFN2 GJB1 GDAP1
2 neuropathy, hereditary motor and sensory, russe type 34.3 NDRG1 GDAP1 EGR2
3 hereditary sensory and autonomic neuropathy type 1 34.2 SPTLC1 LITAF GDAP1
4 charcot-marie-tooth disease, axonal, type 2a1 34.1 MPZ MFN2 GDAP1
5 charcot-marie-tooth disease/hereditary motor and sensory neuropathy 33.9 SPTLC1 SLC12A6 PRX PMP22 MPZ MFN2
6 neuropathy, hereditary sensory and autonomic, type iia 33.9 SPTLC1 SLC12A6 NGF MFN2 LITAF GDAP1
7 charcot-marie-tooth disease, demyelinating, type 1b 33.9 PRX PMP22 MTMR2 MPZ MFN2 LITAF
8 neuropathy, hereditary sensory and autonomic, type ic 33.8 SPTLC1 LITAF
9 roussy-levy hereditary areflexic dystasia 33.7 PMP22 MPZ
10 neuropathy, hereditary sensory and autonomic, type v 33.7 SPTLC1 NGF
11 charcot-marie-tooth disease, axonal, type 2b2 33.6 MPZ MFN2 GDAP1
12 charcot-marie-tooth disease, demyelinating, type 1a 33.5 PRX PMP22 NTF3 MTMR2 MPZ MFN2
13 charcot-marie-tooth disease, type 4d 33.5 NDRG1 MTMR2 MPZ LITAF GJB1 GDAP1
14 charcot-marie-tooth disease, demyelinating, type 1c 33.5 PRX PMP22 MTMR2 MPZ LITAF GJB1
15 charcot-marie-tooth disease, demyelinating, type 1d 33.5 PRX PMP22 MTMR2 MPZ LITAF GJB1
16 charcot-marie-tooth disease, axonal, type 2b 33.3 SPTLC1 MTMR2 MPZ MFN2 LITAF GJB1
17 charcot-marie-tooth disease x-linked recessive 4 33.3 MPZ GJB1
18 charcot-marie-tooth disease, type 4b1 33.2 PRX MTMR2 MPZ LITAF GDAP1 FGD4
19 motor peripheral neuropathy 33.1 SLC12A6 PMP22 MAG LITAF GJB1 GDAP1
20 charcot-marie-tooth disease, axonal, type 2d 33.1 MPZ MFN2 GJB1 GDAP1
21 charcot-marie-tooth disease, type 4a 33.1 PRX MTMR2 MPZ MFN2 GJB1 GDAP1
22 charcot-marie-tooth disease, axonal, type 2b1 33.1 MFN2 GDAP1
23 charcot-marie-tooth disease, type 4b2 33.1 PRX MTMR2 MPZ LITAF GJB1 GDAP1
24 charcot-marie-tooth disease type 2a2a 33.1 MPZ MFN2 LITAF GJB1 GDAP1
25 neuropathy, hereditary, with liability to pressure palsies 33.0 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
26 charcot-marie-tooth disease, x-linked recessive, 2 33.0 MPZ LITAF GJB1 EGR2
27 charcot-marie-tooth disease 33.0 SPTLC1 SLC12A6 PRX PMP22 NTF3 NGF
28 hereditary neuropathies 33.0 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
29 charcot-marie-tooth disease intermediate type 32.9 MTMR2 MPZ MFN2 LITAF GJB1 GDAP1
30 charcot-marie-tooth disease and deafness 32.9 SPTLC1 PRX PMP22 NDRG1 MTMR2 MPZ
31 charcot-marie-tooth disease, axonal, type 2e 32.6 SPTLC1 SLC12A6 PRX PMP22 NGF NDRG1
32 neuropathy, congenital hypomyelinating, 1, autosomal recessive 32.6 SLC12A6 PRX PMP22 NTF3 NDRG1 MTMR2
33 charcot-marie-tooth disease, x-linked dominant, 1 32.1 SPTLC1 PRX PMP22 MTMR2 MPZ MFN2
34 charcot-marie-tooth disease, axonal, type 2n 32.1 MFN2 GDAP1
35 charcot-marie-tooth disease, axonal, type 2p 32.0 LITAF GDAP1
36 charcot-marie-tooth disease, recessive intermediate a 32.0 MFN2 GDAP1
37 charcot-marie-tooth disease, axonal, type 2f 31.9 SPTLC1 MTMR2 MPZ MFN2 GJB1 GDAP1
38 charcot-marie-tooth disease, type 4c 31.7 MTMR2 MPZ MFN2 LITAF GJB1 GDAP1
39 hypertrophic neuropathy of dejerine-sottas 31.7 SPTLC1 PRX PMP22 NDRG1 MTMR2 MPZ
40 charcot-marie-tooth disease, dominant intermediate e 31.6 MTMR2 MPZ GDAP1
41 charcot-marie-tooth disease, dominant intermediate c 31.6 SPTLC1 MPZ GDAP1
42 charcot-marie-tooth disease, axonal, type 2l 31.5 SPTLC1 MPZ MFN2 GDAP1
43 charcot-marie-tooth disease, dominant intermediate a 31.5 PRX MPZ GJB1 GDAP1
44 charcot-marie-tooth disease, axonal, type 2q 31.5 MPZ GJB1 EGR2
45 axonal neuropathy 31.5 PMP22 MFN2 GDAP1
46 charcot-marie-tooth disease, axonal, type 2r 31.5 SLC12A6 GDAP1
47 charcot-marie-tooth disease, demyelinating, type 1f 31.4 MTMR2 MPZ LITAF GJB1 FGD4
48 charcot-marie-tooth disease, type 4b3 31.4 MTMR2 GDAP1
49 charcot-marie-tooth disease, axonal, type 2j 31.4 MTMR2 MPZ MFN2 GDAP1 EGR2
50 charcot-marie-tooth disease, dominant intermediate b 31.4 MTMR2 MPZ LITAF GJB1 GDAP1
51 charcot-marie-tooth disease, type 4j 31.4 PRX MTMR2 LITAF GDAP1 FGD4
52 charcot-marie-tooth disease, axonal, type 2i 31.3 PMP22 MPZ MFN2 LITAF GJB1 GDAP1
53 charcot-marie-tooth disease, type 4h 31.3 PRX NDRG1 MTMR2 MPZ GDAP1 FGD4
54 demyelinating polyneuropathy 31.3 PMP22 NGF MAG
55 charcot-marie-tooth disease, demyelinating, type 4f 31.1 PRX MTMR2 MPZ LITAF GJB1 GDAP1
56 mononeuropathy 31.1 PMP22 NGF MPZ MAG
57 tooth disease 31.1 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
58 diabetic neuropathy 31.0 PMP22 NTF3 NGF MPZ
59 foot drop 31.0 PMP22 MPZ
60 hereditary sensory neuropathy 30.9 SPTLC1 NGF MPZ CCT4
61 mononeuritis multiplex 30.9 PMP22 MAG
62 neurogenic arthropathy 30.9 SPTLC1 NGF
63 neuropathy 30.9 SPTLC1 SLC12A6 PRX PMP22 NGF MTMR2
64 polyradiculoneuropathy 30.8 PMP22 MPZ MAG
65 neuritis 30.8 PMP22 MPZ MAG
66 chronic polyneuropathy 30.8 PMP22 MAG GJB1
67 miller fisher syndrome 30.6 PMP22 MAG
68 autonomic neuropathy 30.6 SPTLC1 NTF3 NGF
69 amyotrophic neuralgia 30.5 PMP22 MPZ
70 peripheral nervous system disease 30.5 SPTLC1 PRX PMP22 NTF3 NGF MTMR2
71 demyelinating disease 30.5 PMP22 NTF3 NGF MPZ MAG
72 polyneuropathy 30.2 PRX PMP22 NGF MPZ MFN2 MAG
73 neuromuscular disease 30.1 PRX PMP22 NDRG1 MTMR2 MPZ MFN2
74 brachial plexus neuropathy 29.8 PMP22 MPZ
75 hereditary motor and sensory neuropathy v 12.8
76 sptlc1-related hereditary sensory neuropathy 12.7
77 deafness, nerve type, with mesenteric diverticula of small bowel and progressive sensory neuropathy 12.6
78 autosomal recessive axonal hereditary motor and sensory neuropathy 12.5
79 hereditary motor and sensory neuropathy with acrodystrophy 12.5
80 neuropathy, hereditary motor and sensory, okinawa type 12.4
81 keratoderma, palmoplantar, with nail dystrophy and hereditary motor-sensory neuropathy 12.4
82 neuropathy, hereditary motor and sensory, type via, with optic atrophy 12.4
83 autosomal dominant hereditary demyelinating motor and sensory neuropathy 12.4
84 autosomal dominant hereditary axonal motor and sensory neuropathy 12.4
85 autosomal recessive hereditary demyelinating motor and sensory neuropathy 12.4
86 hereditary motor and sensory neuropathy with agenesis of the corpus callosum 12.4
87 demyelinating hereditary motor and sensory neuropathy 12.4
88 axonal hereditary motor and sensory neuropathy 12.4
89 gdap1-related hereditary motor and sensory neuropathy 12.4
90 neuropathy, hereditary sensory, type ie 12.3
91 agenesis of the corpus callosum with peripheral neuropathy 12.3
92 neuropathy, hereditary sensory, type if 12.3
93 neuropathy, hereditary sensory, type id 12.3
94 charcot-marie-tooth disease, axonal, autosomal dominant, type 2a2a 12.2
95 obsolete: x-linked recessive hereditary axonal motor and sensory neuropathy 12.2
96 acute pure sensory neuropathy 12.2
97 infantile-onset axonal motor and sensory neuropathy-optic atrophy-neurodegenerative syndrome 12.2
98 insensitivity to pain, congenital, with anhidrosis 12.2
99 neuropathy, hereditary sensory and autonomic, type i, with cough and gastroesophageal reflux 12.1
100 charcot-marie-tooth disease, x-linked recessive, 4, with or without cerebellar ataxia 12.1
101 mitochondrial dna depletion syndrome 7 12.1
102 x-linked charcot-marie-tooth disease 12.0
103 neuropathy, hereditary sensory and autonomic, type ia 12.0
104 neuropathy, hereditary sensory, with spastic paraplegia, autosomal recessive 12.0
105 neuropathy, hereditary sensory, atypical 11.9
106 neuropathy, hereditary sensory, x-linked 11.8
107 neuropathy, hereditary sensory and autonomic, type vi 11.8
108 neuropathy, hereditary motor and sensory, type vib, with optic atrophy 11.8
109 neuropathy, hereditary motor and sensory, type vic, with optic atrophy 11.8
110 autosomal dominant charcot-marie-tooth disease type 2 with giant axons 11.8
111 neuropathy, hereditary motor and sensory, with deafness, mental retardation, and absent sensory large myelinated fibers 11.8
112 giant axonal neuropathy 2, autosomal dominant 11.8
113 spinocerebellar ataxia 25 11.7
114 deafness, x-linked 5, with peripheral neuropathy 11.7
115 refsum disease, classic 11.6
116 cerebellar ataxia, neuropathy, and vestibular areflexia syndrome 11.6
117 charcot-marie-tooth disease, axonal, type 2t 11.6
118 neuropathy, hereditary sensory and autonomic, type iii 11.5
119 charcot-marie-tooth neuropathy type 2a 11.5
120 46,xy gonadal dysgenesis, partial, with minifascicular neuropathy 11.5
121 neuropathy, hereditary sensory, type iic 11.5
122 charcot-marie-tooth disease, x-linked recessive, 3 11.5
123 charcot-marie-tooth disease, x-linked recessive, 5 11.5
124 charcot-marie-tooth disease, axonal, type 2v 11.5
125 neuropathy, ataxia, and retinitis pigmentosa 11.5
126 systemic lupus erythematosus 11.4
127 giant axonal neuropathy 11.4
128 paraneoplastic syndromes 11.4
129 indifference to pain, congenital, autosomal recessive 11.4
130 sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 11.4
131 siddiqi syndrome 11.4
132 intermittent claudication 11.4
133 x-linked hereditary sensory and autonomic neuropathy with deafness 11.4
134 cerebellar ataxia, deafness, and narcolepsy, autosomal dominant 11.4
135 spinocerebellar ataxia, autosomal recessive 16 11.4
136 spinocerebellar ataxia 18 11.3
137 spastic paraplegia 7, autosomal recessive 11.3
138 posterior column ataxia with retinitis pigmentosa 11.2
139 cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia 11.2
140 charcot-marie-tooth disease, demyelinating, type 1g 11.2
141 charcot-marie-tooth disease type 5 11.2
142 charcot-marie-tooth disease type 1g 11.2
143 charcot-marie-tooth hereditary neuropathy 11.2
144 charcot-marie-tooth disease type 2a 11.2
145 charcot-marie-tooth disease with ptosis and parkinsonism 11.1
146 spinocerebellar ataxia 1 11.1
147 pruritus, hereditary localized 11.1
148 chylomicron retention disease 11.1
149 phosphoglycerate dehydrogenase deficiency 11.1
150 spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 1 11.1
151 kanzaki disease 11.1
152 leukoencephalopathy with dystonia and motor neuropathy 11.1
153 peroxisome biogenesis disorder 8b 11.1
154 neuropathy, hereditary sensory and autonomic, type vii 11.1
155 neuropathy, hereditary sensory and autonomic, type viii 11.1
156 mitochondrial complex v deficiency, nuclear type 5 11.1
157 spastic paraplegia 8 11.1
158 spastic paraplegia 11 11.1
159 hamanishi ueba tsuji syndrome 11.1
160 hereditary sensorimotor neuropathy with hyperelastic skin 11.1
161 paraneoplastic neurologic disorders 11.1
162 spastic paraplegia 15 11.1
163 ataxia neuropathy spectrum 11.1
164 lupus - neurological sequelae 11.1
165 familial syringomyelia 11.1
166 charcot-marie-tooth disease, dominant intermediate d 10.8
167 charcot-marie-tooth disease, dominant intermediate f 10.8
168 charcot-marie-tooth disease, recessive intermediate d 10.8
169 slowed nerve conduction velocity, autosomal dominant 10.8
170 autosomal dominant charcot-marie-tooth disease type 2g 10.8
171 facial onset sensory and motor neuronopathy 10.7
172 ataxia and polyneuropathy, adult-onset 10.7
173 argyll robertson pupil 10.7 MPZ GDAP1
174 pupil disease 10.7 MPZ GDAP1
175 abnormal pupillary function 10.6 MPZ GDAP1 EGR2
176 autoimmune peripheral neuropathy 10.6 MPZ MAG GJB1
177 asymmetric motor neuropathy 10.6 PMP22 MFN2 MAG
178 autoimmune neuropathy 10.6 PMP22 MPZ MAG
179 charcot-marie-tooth disease, axonal, type 2cc 10.6 MPZ MFN2 GJB1
180 autoimmune disease of peripheral nervous system 10.6 PMP22 MPZ MAG
181 mononeuritis of lower limb 10.6 PMP22 NTF3 NGF
182 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 10.6 MPZ GJB1 EGR2
183 nerve compression syndrome 10.6 PMP22 NGF MPZ
184 lesion of sciatic nerve 10.6 PMP22 NTF3 NGF
185 lumbosacral plexus lesion 10.6 NTF3 NGF
186 mononeuritis of upper limb and mononeuritis multiplex 10.6 PMP22 MAG
187 pelizaeus-merzbacher disease 10.6 PMP22 MPZ MAG
188 muscular atrophy 10.5
189 anhidrosis 10.5
190 ocular dominance 10.5 NTF3 NGF
191 charcot-marie-tooth disease, x-linked dominant, 6 10.5
192 charcot-marie-tooth disease, axonal, type 2h 10.5
193 charcot-marie-tooth disease, axonal, type 2k 10.5
194 charcot-marie-tooth disease, recessive intermediate b 10.5
195 charcot-marie-tooth disease, axonal, type 2o 10.5
196 charcot-marie-tooth disease, recessive intermediate c 10.5
197 charcot-marie-tooth disease, axonal, type 2u 10.5
198 charcot-marie-tooth disease, type 4k 10.5
199 pontocerebellar hypoplasia, type 7 10.4 ELAVL4 ELAVL3
200 paraplegia 10.4
201 rett syndrome 10.4 NGF MAG GJB1 EGR2
202 cataract 38 10.4 NTF3 NGF
203 aceruloplasminemia 10.4
204 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
205 autonomic dysfunction 10.4
206 charcot-marie-tooth disease type x 10.3 SPTLC1 PMP22 MTMR2 MPZ MFN2 GJB1
207 3-methylglutaconic aciduria, type iii 10.3
208 connective tissue disease 10.3
209 pure autonomic failure 10.3
210 neuromyotonia and axonal neuropathy, autosomal recessive 10.3
211 neuropathy, hereditary thermosensitive 10.3
212 neuropathy, hereditary, with or without age-related macular degeneration 10.3
213 peripheral neuropathy, myopathy, hoarseness, and hearing loss 10.3
214 charcot-marie-tooth disease type 2a2b 10.3
215 autosomal dominant intermediate charcot-marie-tooth 10.3
216 autosomal recessive intermediate charcot-marie-tooth disease 10.3
217 autosomal dominant charcot-marie-tooth disease type 2 due to kif5a mutation 10.3
218 autosomal dominant intermediate charcot-marie-tooth disease with neuropathic pain 10.3
219 autosomal dominant charcot-marie-tooth disease type 2 due to tfg mutation 10.3
220 dnajb2-related charcot-marie-tooth disease type 2 10.3
221 autosomal recessive disease 10.3
222 scoliosis 10.3
223 guillain-barre syndrome 10.3
224 amyotrophic lateral sclerosis 1 10.3
225 erythermalgia, primary 10.3
226 pain sensitivity quantitative trait locus 1 10.3
227 lateral sclerosis 10.3
228 wallerian degeneration 10.3 MPZ MAG
229 small cell carcinoma 10.2
230 osteomyelitis 10.2
231 motor neuron disease 10.2
232 hansen's disease 10.2
233 leprosy 3 10.2
234 myopathy 10.2
235 myotonic dystrophy 10.2
236 hypotonia 10.2
237 tremor 10.2
238 spinal muscular atrophy 10.2
239 autosomal dominant cerebellar ataxia 10.2
240 hereditary spastic paraplegia 10.2
241 mixed connective tissue disease 10.2
242 chronic inflammatory demyelinating polyradiculoneuropathy 10.2
243 dystonia 10.2
244 syncope 10.2
245 kearns-sayre syndrome 10.2
246 dysautonomia 10.2
247 immune deficiency disease 10.1
248 vasculitis 10.1
249 colorectal cancer 10.1
250 carpal tunnel syndrome 10.1
251 keratitis, hereditary 10.1
252 scleroderma, familial progressive 10.1
253 muscle hypertrophy 10.1
254 sensorineural hearing loss 10.1
255 respiratory failure 10.1
256 bell's palsy 10.1
257 systemic scleroderma 10.1
258 spasticity 10.1
259 sarcoidosis 1 10.0
260 small cell cancer of the lung 10.0
261 retinitis pigmentosa 10.0
262 lymphoma 10.0
263 neuroretinitis 10.0
264 dementia 10.0
265 facial paralysis 10.0
266 retinitis 10.0
267 encephalitis 10.0
268 charcot-marie-tooth neuropathy x type 1 10.0
269 auditory neuropathy spectrum disorder 10.0
270 spinocerebellar degeneration 10.0
271 hyperglycemia 10.0
272 diabetes mellitus 10.0
273 alcohol dependence 10.0
274 candidiasis, familial, 1 10.0
275 rheumatoid arthritis 10.0
276 spastic paraplegia 3, autosomal dominant 10.0
277 trigeminal neuralgia 10.0
278 friedreich ataxia 10.0
279 lymphoma, hodgkin, classic 10.0
280 neuronopathy, distal hereditary motor, type viii 10.0
281 lymphoma, non-hodgkin, familial 10.0
282 intraocular pressure quantitative trait locus 10.0
283 exanthem 10.0
284 sleep apnea 10.0
285 hereditary ataxia 10.0
286 dermatomyositis 10.0
287 primary biliary cirrhosis 10.0
288 hypothyroidism 10.0
289 ichthyosis 10.0
290 squamous cell carcinoma 10.0
291 impotence 10.0
292 hepatitis c 10.0
293 constipation 10.0
294 radiculopathy 10.0
295 liver cirrhosis 10.0
296 human immunodeficiency virus infectious disease 10.0
297 chickenpox 10.0
298 amyloidosis 10.0
299 erythromelalgia 10.0
300 pathologic nystagmus 10.0
301 muscular dystrophy 10.0
302 dnmt1-related disorder 10.0
303 trpv4-associated disorders 10.0
304 autoimmune autonomic ganglionopathy 10.0
305 cerebellar degeneration 10.0
306 limbic encephalitis 10.0
307 polymyositis 10.0
308 raynaud phenomenon 10.0
309 encephalopathy 10.0
310 paraneoplastic limbic encephalitis 10.0
311 neurotrophic keratopathy 10.0
312 anisocoria 9.9
313 atrial standstill 1 9.9
314 machado-joseph disease 9.9
315 gastroesophageal reflux 9.9
316 breast cancer 9.9
317 dentatorubral-pallidoluysian atrophy 9.9
318 myositis 9.9
319 myotonic dystrophy 1 9.9
320 scapuloperoneal spinal muscular atrophy 9.9
321 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 9.9
322 proteasome-associated autoinflammatory syndrome 1 9.9
323 neuropathy, hereditary motor and sensory, with excessive myelin folding complex, autosomal recessive 9.9
324 sjogren syndrome 9.9
325 spastic ataxia, charlevoix-saguenay type 9.9
326 thymoma, familial 9.9
327 paine syndrome 9.9
328 microvascular complications of diabetes 1 9.9
329 glucose intolerance 9.9
330 neurogenic bladder 9.9
331 hepatitis a 9.9
332 chronic progressive external ophthalmoplegia 9.9
333 amenorrhea 9.9
334 gonadal dysgenesis 9.9
335 status epilepticus 9.9
336 urethral stricture 9.9
337 neuroma 9.9
338 hepatitis 9.9
339 dermatitis 9.9
340 spinal cord disease 9.9
341 myelitis 9.9
342 thymoma 9.9
343 ulnar neuropathy 9.9
344 monoclonal gammopathy of uncertain significance 9.9
345 cataract 9.9
346 ileus 9.9
347 herpes simplex 9.9
348 lupus erythematosus 9.9
349 achalasia 9.9
350 homocystinuria 9.9
351 charcot-marie-tooth neuropathy x type 5 9.9
352 spastic paraplegia 3a 9.9
353 athetosis 9.9
354 marek disease 9.9
355 cytomegalovirus infection 9.9
356 myotonia 9.9
357 muscular lipidosis 9.9
358 acute pandysautonomia 9.9
359 autoimmune disease 9.9
360 diabetes mellitus, noninsulin-dependent 9.9
361 pheochromocytoma 9.9
362 syringomyelia, noncommunicating isolated 9.9
363 alstrom syndrome 9.9
364 tay-sachs disease 9.9
365 yemenite deaf-blind hypopigmentation syndrome 9.9
366 branchiootic syndrome 1 9.9
367 human immunodeficiency virus type 1 9.9
368 microvascular complications of diabetes 5 9.9
369 gastric cancer 9.9
370 glucocorticoid deficiency 4 with or without mineralocorticoid deficiency 9.9
371 peripheral vascular disease 9.9
372 vitamin b12 deficiency 9.9
373 limb ischemia 9.9
374 adrenal gland pheochromocytoma 9.9
375 bone resorption disease 9.9
376 allergic hypersensitivity disease 9.9
377 beriberi 9.9
378 alcohol use disorder 9.9
379 thrombocytopenia 9.9
380 vascular disease 9.9
381 optic nerve disease 9.9
382 cerebral palsy 9.9
383 epidermolysis bullosa 9.9
384 syringomyelia 9.9
385 central nervous system disease 9.9
386 gm2 gangliosidosis 9.9
387 arthropathy 9.9
388 epidermolysis bullosa acquisita 9.9
389 pustulosis of palm and sole 9.9
390 uremia 9.9
391 acquired immunodeficiency syndrome 9.9
392 nervous system disease 9.9
393 psoriasis 9.9
394 lichen planus 9.9
395 47,xyy 9.9
396 gangliosidosis 9.9
397 linear iga disease 9.9
398 notalgia paresthetica 9.9
399 oral lichen planus 9.9
400 spastic paraparesis 9.9
401 chronic pain 9.9
402 dysphagia 9.9
403 paresthesia 9.9
404 acanthosis nigricans 9.7
405 acroosteolysis 9.7
406 adie pupil 9.7
407 aplasia cutis congenita, nonsyndromic 9.7
408 cardiac conduction defect 9.7
409 charcot-marie-tooth disease, guadalajara neuronal type 9.7
410 multiple sclerosis 9.7
411 multiple self-healing squamous epithelioma 9.7
412 hypertelorism 9.7
413 hypertriglyceridemia, familial 9.7
414 multiple system atrophy 1 9.7
415 ichthyosis vulgaris 9.7
416 inclusion body myositis 9.7
417 lipomatosis, multiple 9.7
418 meralgia paraesthetica, familial 9.7
419 metatropic dysplasia 9.7
420 migraine with or without aura 1 9.7
421 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 1 9.7
422 facioscapulohumeral muscular dystrophy 1 9.7
423 myoclonus and ataxia 9.7
424 amyotrophy, hereditary neuralgic 9.7
425 neurofibromatosis, type iv, of riccardi 9.7
426 optic atrophy 1 9.7
427 posterior column ataxia 9.7
428 vitiligo-associated multiple autoimmune disease susceptibility 6 9.7
429 tangier disease 9.7
430 ataxia-telangiectasia 9.7
431 autism 9.7
432 lung cancer 9.7
433 cerebellar ataxia, early-onset, with retained tendon reflexes 9.7
434 congenital heart defects, hamartomas of tongue, and polysyndactyly 9.7
435 diabetes mellitus, insulin-dependent 9.7
436 galactorrhea 9.7
437 multiple acyl-coa dehydrogenase deficiency 9.7
438 glycogen storage disease ii 9.7
439 perrault syndrome 1 9.7
440 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.7
441 marinesco-sjogren syndrome 9.7
442 mucolipidosis iii alpha/beta 9.7
443 spinal muscular atrophy, type i 9.7
444 myasthenia gravis 9.7
445 arts syndrome 9.7
446 charcot-marie-tooth peroneal muscular atrophy, x-linked, with aplasia cutis congenita 9.7
447 spinal and bulbar muscular atrophy, x-linked 1 9.7
448 cyclic vomiting syndrome 9.7
449 aging 9.7
450 gallbladder disease 1 9.7
451 glaucoma 3, primary infantile, b 9.7
452 dermatitis herpetiformis, familial 9.7
453 macular degeneration, age-related, 1 9.7
454 spinocerebellar ataxia 12 9.7
455 orthostatic intolerance 9.7
456 spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 9.7
457 vitiligo-associated multiple autoimmune disease susceptibility 1 9.7
458 spinocerebellar ataxia 15 9.7
459 spinocerebellar ataxia 17 9.7
460 spinocerebellar ataxia, autosomal recessive 4 9.7
461 spinocerebellar ataxia 8 9.7
462 auditory neuropathy, autosomal dominant, 1 9.7
463 spastic paraplegia 30, autosomal recessive 9.7
464 microvascular complications of diabetes 2 9.7
465 neuropathy, hereditary sensory and autonomic, type iib 9.7
466 graft-versus-host disease 9.7
467 pseudohypoaldosteronism, type iie 9.7
468 spastic paraplegia 55, autosomal recessive 9.7
469 spinal muscular atrophy, lower extremity-predominant, 2a, childhood onset, autosomal dominant 9.7
470 alacrima, achalasia, and mental retardation syndrome 9.7
471 charcot-marie-tooth disease, axonal, type 2z 9.7
472 auditory neuropathy and optic atrophy 9.7
473 alkuraya-kucinskas syndrome 9.7
474 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
475 rocky mountain spotted fever 9.7
476 aspiration pneumonia 9.7
477 lambert-eaton myasthenic syndrome 9.7
478 restless legs syndrome 9.7
479 distal arthrogryposis 9.7
480 perrault syndrome 9.7
481 tonsil squamous cell carcinoma 9.7
482 autosomal recessive cerebellar ataxia 9.7
483 spastic ataxia 9.7
484 apraxia 9.7
485 pain agnosia 9.7
486 physical urticaria 9.7
487 inguinal hernia 9.7
488 drug allergy 9.7
489 dry beriberi 9.7
490 mucolipidosis 9.7
491 autosomal recessive limb-girdle muscular dystrophy 9.7
492 autosomal recessive limb-girdle muscular dystrophy type 2a 9.7
493 tabes dorsalis 9.7
494 osteonecrosis 9.7
495 pleomorphic lipoma 9.7
496 sialadenitis 9.7
497 silicosis 9.7
498 lymphocytic leukemia 9.7
499 microinvasive gastric cancer 9.7
500 leukodystrophy 9.7
501 open-angle glaucoma 9.7
502 juvenile glaucoma 9.7
503 gastric ulcer 9.7
504 amnestic disorder 9.7
505 spotted fever 9.7
506 sarcoma 9.7
507 primary hyperparathyroidism 9.7
508 tetanus 9.7
509 cauda equina syndrome 9.7
510 infant gynecomastia 9.7
511 lyme disease 9.7
512 clubfoot 9.7
513 conn's syndrome 9.7
514 optic neuritis 9.7
515 hemosiderosis 9.7
516 low compliance bladder 9.7
517 goiter 9.7
518 common variable immunodeficiency 9.7
519 locked-in syndrome 9.7
520 gynecomastia 9.7
521 telangiectasis 9.7
522 diabetic polyneuropathy 9.7
523 quadriplegia 9.7
524 keratoconjunctivitis sicca 9.7
525 dilated cardiomyopathy 9.7
526 hereditary spherocytosis 9.7
527 acute cystitis 9.7
528 megaesophagus 9.7
529 diarrhea 9.7
530 pulmonary sarcoidosis 9.7
531 hyperparathyroidism 9.7
532 multiple cranial nerve palsy 9.7
533 alcoholic neuropathy 9.7
534 46 xx gonadal dysgenesis 9.7
535 urticaria 9.7
536 rheumatic disease 9.7
537 keratosis 9.7
538 melanoma 9.7
539 hypogonadism 9.7
540 hepatitis b 9.7
541 amelogenesis imperfecta 9.7
542 gastroenteritis 9.7
543 wernicke encephalopathy 9.7
544 agammaglobulinemia 9.7
545 synovitis 9.7
546 contact dermatitis 9.7
547 laryngeal squamous cell carcinoma 9.7
548 cryoglobulinemia 9.7
549 adenocarcinoma 9.7
550 acute kidney failure 9.7
551 churg-strauss syndrome 9.7
552 papillary adenocarcinoma 9.7
553 progressive muscular atrophy 9.7
554 complex regional pain syndrome 9.7
555 temporal lobe epilepsy 9.7
556 palmoplantar keratosis 9.7
557 signet ring cell adenocarcinoma 9.7
558 superior mesenteric artery syndrome 9.7
559 bladder disease 9.7
560 ovary adenocarcinoma 9.7
561 intestinal pseudo-obstruction 9.7
562 syphilis 9.7
563 spindle cell sarcoma 9.7
564 burning mouth syndrome 9.7
565 amelanotic melanoma 9.7
566 seminoma 9.7
567 macular retinal edema 9.7
568 pseudohypoaldosteronism 9.7
569 movement disease 9.7
570 adenosquamous carcinoma 9.7
571 essential tremor 9.7
572 sleep disorder 9.7
573 internuclear ophthalmoplegia 9.7
574 eye disease 9.7
575 gastric adenosquamous carcinoma 9.7
576 congestive heart failure 9.7
577 fibromyalgia 9.7
578 prion disease 9.7
579 cerebrovascular disease 9.7
580 b-cell lymphoma 9.7
581 hypogonadotropism 9.7
582 diverticulitis 9.7
583 peptic ulcer disease 9.7
584 end stage renal failure 9.7
585 myocarditis 9.7
586 paralytic ileus 9.7
587 arthritis 9.7
588 dermatitis herpetiformis 9.7
589 bullous pemphigoid 9.7
590 malignant hyperthermia 9.7
591 decubitus ulcer 9.7
592 narcolepsy 9.7
593 primary cerebellar degeneration 9.7
594 keratoconjunctivitis 9.7
595 neurofibroma 9.7
596 episodic ataxia 9.7
597 alopecia 9.7
598 hypereosinophilic syndrome 9.7
599 hypoglycemia 9.7
600 limb-girdle muscular dystrophy 9.7
601 gnptab-related disorders 9.7
602 mitochondrial disorders 9.7
603 vps13d movement disorder 9.7
604 adrenomyeloneuropathy 9.7
605 allergic angiitis 9.7
606 amyloid neuropathy 9.7
607 autoimmune gastrointestinal dysmotility 9.7
608 broken heart syndrome 9.7
609 cold urticaria 9.7
610 dwarfism 9.7
611 growth hormone deficiency 9.7
612 hashimoto encephalopathy 9.7
613 localized hypertrophic neuropathy 9.7
614 pyridoxine deficiency 9.7
615 rheumatoid vasculitis 9.7
616 transverse myelitis 9.7
617 undifferentiated connective tissue disease 9.7
618 angiomatosis 9.7
619 cerebral beriberi 9.7
620 headache 9.7
621 myoclonus 9.7
622 postherpetic neuralgia 9.7
623 b-cell non-hodgkin lymphoma 9.7
624 inherited prion disease 9.7
625 specific language disorder 9.7
626 rare hereditary hemochromatosis 9.7
627 toxic oil syndrome 9.7
628 autosomal recessive spastic ataxia 9.7
629 acyl-coa dehydrogenase deficiency 9.7
630 cerebellar ataxia with neuropathy and bilateral vestibular areflexia syndrome 9.7
631 common mesentery 9.7
632 familial keratoacanthoma 9.7
633 congenital amyoplasia 9.7
634 bickerstaff brainstem encephalitis 9.7
635 transient pseudohypoaldosteronism 9.7
636 cardiogenic shock 9.7
637 rare peripheral neuropathy 9.7
638 pure hereditary spastic paraplegia 9.7
639 thyroid carcinoma 9.7

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


hyperesthesia, dysesthesia, sciatica, neurologic symptoms

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

26 (showing 43, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.39 GJB1
2 Decreased viability GR00221-A-1 10.39 ELAVL4
3 Decreased viability GR00221-A-2 10.39 ELAVL4
4 Decreased viability GR00381-A-1 10.39 FGD4 MPZ PRX
5 Decreased viability GR00381-A-3 10.39 MPZ
6 Decreased viability GR00402-S-2 10.39 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.23 FGD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.23 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.23 SLC12A6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-108 10.23 NTF3
11 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.23 FGD4 GJB1 NTF3 SLC12A6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.23 NTF3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.23 FGD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-140 10.23 FGD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-143 10.23 GJB1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.23 FGD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.23 NTF3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.23 GJB1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.23 SLC12A6
20 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.23 SLC12A6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.23 GJB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.23 SLC12A6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.23 SLC12A6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.23 NTF3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.23 FGD4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.23 GJB1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.23 SLC12A6
28 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.23 GJB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.23 SLC12A6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-26 10.23 NTF3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.23 SLC12A6
32 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.23 SLC12A6
33 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.23 GJB1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-51 10.23 GJB1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-56 10.23 FGD4
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.23 NTF3
37 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.23 SLC12A6
38 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.23 SLC12A6
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.23 NTF3
40 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10.23 FGD4
41 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.23 SLC12A6
42 Increased gamma-H2AX phosphorylation GR00053-A 9.81 CCT4 EGR2 ELAVL4 GJB1 MAG MPZ
43 no effect GR00402-S-1 9.62 CCT4 EGR2 ELAVL3 ELAVL4 FGD4 FLVCR1

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

45 (showing 6, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.3 EGR2 ELAVL3 ELAVL4 FGD4 GDAP1 GJB1
2 growth/size/body region MP:0005378 10.13 EGR2 FGD4 FLVCR1 GJB1 MFN2 MPZ
3 homeostasis/metabolism MP:0005376 10.13 EGR2 ELAVL3 ELAVL4 FLVCR1 GDAP1 GJB1
4 mortality/aging MP:0010768 9.97 EGR2 ELAVL3 ELAVL4 FLVCR1 GJB1 MFN2
5 nervous system MP:0003631 9.91 EGR2 ELAVL3 ELAVL4 FGD4 GDAP1 GJB1
6 reproductive system MP:0005389 9.32 EGR2 ELAVL4 FLVCR1 GDAP1 MPZ MTMR2

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 181, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
2
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
5
Nortriptyline Approved Phase 4 72-69-5 4543
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
8
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
9
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
10
Cobalamin Experimental Phase 4 13408-78-1 6857388
11 Vitamin B Complex Phase 4
12 Vitamin B 12 Phase 4
13 Vitamin B12 Phase 4
14 Vitamin B 6 Phase 4
15 Adrenergic Agents Phase 4
16 Anesthetics, Local Phase 4
17 Anti-Arrhythmia Agents Phase 4
18 Sodium Channel Blockers Phase 4
19 Anesthetics Phase 4
20 Diuretics, Potassium Sparing Phase 4
21 Antidepressive Agents, Tricyclic Phase 4
22 Excitatory Amino Acids Phase 4
23 Excitatory Amino Acid Antagonists Phase 4
24 Antimanic Agents Phase 4
25
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
26
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
27
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
28
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
29
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
30
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
31
Baclofen Approved Phase 3 1134-47-0 2284
32
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
33
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
34
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
35
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
36
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
37
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
38
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
39
Olaparib Approved Phase 3 763113-22-0 23725625
40
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
41
Dopamine Approved Phase 2, Phase 3 51-61-6, 62-31-7 681
42
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
43
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
44
Perphenazine Approved Phase 2, Phase 3 58-39-9 4748
45
Amitriptyline Approved Phase 2, Phase 3 50-48-6 2160
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
47 Tocotrienol Investigational Phase 3 6829-55-6
48
Cediranib Investigational Phase 3 288383-20-0 9933475
49
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
50
Xaliproden Investigational Phase 3 135354-02-8, 428863-50-7 128919
51 glutamine Phase 3
52 taxane Phase 3
53 Vinca Alkaloids Phase 3
54 Tocopherols Phase 3
55 Tocotrienols Phase 3
56 incobotulinumtoxinA Phase 3
57 Acetylcholine Release Inhibitors Phase 3
58 Neuromuscular Agents Phase 3
59 abobotulinumtoxinA Phase 3
60 Botulinum Toxins Phase 3
61 Cholinergic Agents Phase 3
62 Botulinum Toxins, Type A Phase 3
63 Anesthetics, Dissociative Phase 3
64 Anesthetics, General Phase 3
65 Anesthetics, Intravenous Phase 3
66 Antidotes Phase 3
67 Antiviral Agents Phase 3
68 Antibiotics, Antitubercular Phase 3
69
Liposomal doxorubicin Phase 3 31703
70 Protein Kinase Inhibitors Phase 3
71 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
72 Neurotransmitter Agents Phase 2, Phase 3
73 Analgesics Phase 2, Phase 3
74 Psychotropic Drugs Phase 2, Phase 3
75 Antidepressive Agents Phase 2, Phase 3
76 Dopamine Agents Phase 2, Phase 3
77 Duloxetine Hydrochloride Phase 2, Phase 3
78 Serotonin and Noradrenaline Reuptake Inhibitors Phase 2, Phase 3
79 Antimitotic Agents Phase 3
80 Albumin-Bound Paclitaxel Phase 3
81 Halichondrin B Phase 3
82 Serotonin 5-HT1 Receptor Agonists Phase 3
83 Serotonin Agents Phase 3
84 Cola Phase 3
85 Serotonin Receptor Agonists Phase 3
86 Immunosuppressive Agents Phase 3
87 Analgesics, Non-Narcotic Phase 2, Phase 3
88 Antipsychotic Agents Phase 2, Phase 3
89 Amitriptyline, perphenazine drug combination Phase 2, Phase 3
90 Anti-Infective Agents Phase 3
91 Anti-Bacterial Agents Phase 3
92
Serotonin Investigational, Nutraceutical Phase 2, Phase 3 50-67-9 5202
93
Midazolam Approved, Illicit Phase 2 59467-70-8 4192
94
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6, 103577-45-3 9578005
95
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
96
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
97
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
98
Topiramate Approved Phase 2 97240-79-4 5284627
99
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
100
Fluorouracil Approved Phase 2 51-21-8 3385
101
leucovorin Approved Phase 2 58-05-9 6006 143
102
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
103
Gemcitabine Approved Phase 2 95058-81-4 60750
104
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
105
Aspartic acid Approved, Nutraceutical Phase 2 56-84-8 5960